Gresham Smith is currently providing design and engineering services for the new 250,000-square-foot Coquí RadioPharmaceuticals Corp. medical isotope facility. Coquí Pharma is working toward becoming the first U.S. commercial supplier of the lifesaving radioisotope Molybdenum-99 (Mo-99), which is used in 20 million procedures each year in the U.S. Because of a very short lifespan, the isotope needs to be used in patients quickly after it is created. A major challenge for the industry is that the isotope is not produced in the U.S., and when a production facility in Canada is closed in 2018, there will be no producer from which to purchase Mo-99 in North America. The new facility will utilize sustainable design, construction and operational practices to support successful domestic production of the isotope.
Because of the many unique aspects of this facility, Gresham Smith brought together a multi-disciplined team of architects, engineers, environmental scientists, interior designers and planners from the firm’s Industrial, Environmental, Corporate + Urban Design and Land Planning markets. The design features a beautiful landscape, a stunning corporate headquarters, and a state-of-the-art isotope production facility. The project will support the company’s unique production needs with highly tailored process-driven design, while also serving as an inspiring, modern and sustainable landmark.
The design will ensure Coquí Pharma operates on a minimum energy consumption rate with limited carbon dioxide emissions by mitigating solar exposure and enhancing the control of daylight throughout the building. Water efficiency is also a feature, with the most effective use of water inside the facility as well as for the lush, tropical landscaping to be employed.